Merck, PHR1307-1G, Captopril

General description
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Captopril acts by inhibiting the angiotensin-converting enzyme and is known as an antihypertensive agent. It finds wide use in the treatment of congestive heart failure.
Application
Captopril may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by various analytical techniques.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
Biochem/physiol Actions
Angiotensin converting enzyme inhibitor. Inhibits the formation of angiotensin II, a bioactive peptide that stimulates angiogenesis and increases microvessel density.
Analysis Note
These secondary standards offer multi-traceability to the USP and EP (PhEur) primary standards, where they are available.
Other Notes
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
To see an example of a Certificate of Analysis for this material enter LRAA0067 in the slot below. This is an example certificate only and may not be the lot that you receive.